Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors
- 15 October 2019
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 314, 1-11
- https://doi.org/10.1016/j.jconrel.2019.10.024
Abstract
No abstract availableKeywords
Funding Information
- IWT-Vlaanderen
- Innoviris Attract – Brains for Brussels
- “Kom op tegen Kanker”, “Stichting tegen Kanker” and Research Foundation Flanders
- “Kom Op Tegen Kanker”
- VUB-IOF and VUB-Strategic Research Program
- J.A.V.G.; a FWO-SBO
This publication has 24 references indexed in Scilit:
- PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody FragmentsJournal of Nuclear Medicine, 2015
- Radioimmunotherapy of human tumoursNature Reviews Cancer, 2015
- Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancerExpert Opinion on Drug Delivery, 2014
- Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 NanobodyTheranostics, 2014
- Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage PopulationCancer Research, 2014
- Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor ImmunityCancer Cell, 2013
- Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic NanobodiesLeukemia, 2013
- Nanobody-Based Targeting of the Macrophage Mannose Receptor for EffectiveIn VivoImaging of Tumor-Associated MacrophagesCancer Research, 2012
- Maximizing tumour exposure to anti‐neuropilin‐1 antibody requires saturation of non‐tumour tissue antigenic sinks in miceBritish Journal of Pharmacology, 2012
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) MonocytesCancer Research, 2010